Cardiff Oncology Net Income
| CRDF Stock | USD 1.57 0.03 1.88% |
As of the 12th of February 2026, Cardiff Oncology shows the Risk Adjusted Performance of (0.03), standard deviation of 6.4, and Mean Deviation of 4.07. Cardiff Oncology technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cardiff Oncology information ratio, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Cardiff Oncology is priced correctly, providing market reflects its regular price of 1.57 per share. Please also double-check Cardiff Oncology jensen alpha, which is currently at (0.55) to validate the company can sustain itself at a future point.
Cardiff Oncology Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 89.4768 | Revenue | Earnings Share (0.79) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -40.9 M | -38.8 M | |
| Net Loss | -40.9 M | -42.9 M | |
| Net Loss | -34.9 M | -36.6 M | |
| Net Loss | (0.86) | (0.90) | |
| Net Income Per E B T | 1.13 | 1.10 |
Cardiff | Net Income | Build AI portfolio with Cardiff Stock |
The Net Income trend for Cardiff Oncology offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Cardiff Oncology is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Cardiff Oncology's Net Income Growth Pattern
Below is the plot of the Net Income of Cardiff Oncology over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cardiff Oncology financial statement analysis. It represents the amount of money remaining after all of Cardiff Oncology operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cardiff Oncology's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cardiff Oncology's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (45.43 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cardiff Net Income Regression Statistics
| Arithmetic Mean | (24,863,220) | |
| Coefficient Of Variation | (55.88) | |
| Mean Deviation | 11,930,756 | |
| Median | (24,907,000) | |
| Standard Deviation | 13,894,134 | |
| Sample Variance | 193T | |
| Range | 43.2M | |
| R-Value | (0.84) | |
| Mean Square Error | 61.1T | |
| R-Squared | 0.70 | |
| Significance | 0.000026 | |
| Slope | (2,307,231) | |
| Total Sum of Squares | 3088.8T |
Cardiff Net Income History
Other Fundumenentals of Cardiff Oncology
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cardiff Oncology Net Income component correlations
Cardiff Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cardiff Oncology is extremely important. It helps to project a fair market value of Cardiff Stock properly, considering its historical fundamentals such as Net Income. Since Cardiff Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cardiff Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cardiff Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does Cardiff have expansion opportunities? Factors like these will boost the valuation of Cardiff Oncology. Projected growth potential of Cardiff fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cardiff Oncology demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding Cardiff Oncology requires distinguishing between market price and book value, where the latter reflects Cardiff's accounting equity. The concept of intrinsic value - what Cardiff Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cardiff Oncology's price substantially above or below its fundamental value.
It's important to distinguish between Cardiff Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardiff Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cardiff Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cardiff Oncology 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cardiff Oncology's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cardiff Oncology.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Cardiff Oncology on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Cardiff Oncology or generate 0.0% return on investment in Cardiff Oncology over 90 days. Cardiff Oncology is related to or competes with Applied Therapeutics, Corbus Pharmaceuticals, Elicio Therapeutics, Molecular Partners, Forte Biosciences, PepGen, and Rani Therapeutics. Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California More
Cardiff Oncology Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cardiff Oncology's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cardiff Oncology upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 45.59 | |||
| Value At Risk | (6.82) | |||
| Potential Upside | 9.28 |
Cardiff Oncology Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cardiff Oncology's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cardiff Oncology's standard deviation. In reality, there are many statistical measures that can use Cardiff Oncology historical prices to predict the future Cardiff Oncology's volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.55) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (0.11) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cardiff Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cardiff Oncology February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.10) | |||
| Mean Deviation | 4.07 | |||
| Coefficient Of Variation | (2,193) | |||
| Standard Deviation | 6.4 | |||
| Variance | 40.91 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.55) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 45.59 | |||
| Value At Risk | (6.82) | |||
| Potential Upside | 9.28 | |||
| Skewness | (1.87) | |||
| Kurtosis | 9.31 |
Cardiff Oncology Backtested Returns
Cardiff Oncology secures Sharpe Ratio (or Efficiency) of -0.0349, which signifies that the company had a -0.0349 % return per unit of risk over the last 3 months. Cardiff Oncology exposes twenty different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Cardiff Oncology's Risk Adjusted Performance of (0.03), mean deviation of 4.07, and Standard Deviation of 6.4 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.66, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cardiff Oncology will likely underperform. At this point, Cardiff Oncology has a negative expected return of -0.23%. Please make sure to confirm Cardiff Oncology's value at risk, as well as the relationship between the kurtosis and day typical price , to decide if Cardiff Oncology performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.77 |
Almost perfect reverse predictability
Cardiff Oncology has almost perfect reverse predictability. Overlapping area represents the amount of predictability between Cardiff Oncology time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cardiff Oncology price movement. The serial correlation of -0.77 indicates that around 77.0% of current Cardiff Oncology price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.77 | |
| Spearman Rank Test | -0.66 | |
| Residual Average | 0.0 | |
| Price Variance | 0.38 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Cardiff Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cardiff Oncology reported net income of (45.43 Million). This is 113.31% lower than that of the Biotechnology sector and 164.86% lower than that of the Health Care industry. The net income for all United States stocks is 107.96% higher than that of the company.
Cardiff Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cardiff Oncology's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cardiff Oncology could also be used in its relative valuation, which is a method of valuing Cardiff Oncology by comparing valuation metrics of similar companies.Cardiff Oncology is currently under evaluation in net income category among its peers.
Cardiff Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Cardiff Oncology that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cardiff Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cardiff Oncology's value.| Shares | Nuveen, Llc | 2025-06-30 | 560.3 K | Susquehanna International Group, Llp | 2025-06-30 | 529.1 K | Mccormack Advisors International | 2025-06-30 | 505.2 K | Two Sigma Investments Llc | 2025-06-30 | 443.5 K | Bank Of New York Mellon Corp | 2025-06-30 | 334 K | Marshall Wace Asset Management Ltd | 2025-06-30 | 298.7 K | Two Sigma Advisers, Llc | 2025-06-30 | 205.6 K | Ubs Group Ag | 2025-06-30 | 197.4 K | Royal Bank Of Canada | 2025-06-30 | 191.5 K | Blackrock Inc | 2025-06-30 | 3.9 M | Vanguard Group Inc | 2025-06-30 | 3.7 M |
Cardiff Fundamentals
| Return On Equity | -1.03 | ||||
| Return On Asset | -0.53 | ||||
| Operating Margin | (99.78) % | ||||
| Current Valuation | 44.83 M | ||||
| Shares Outstanding | 67.36 M | ||||
| Shares Owned By Insiders | 5.97 % | ||||
| Shares Owned By Institutions | 35.11 % | ||||
| Number Of Shares Shorted | 17.19 M | ||||
| Price To Earning | (0.48) X | ||||
| Price To Book | 2.14 X | ||||
| Price To Sales | 208.40 X | ||||
| Revenue | 683 K | ||||
| Gross Profit | (39.47 M) | ||||
| EBITDA | (48.25 M) | ||||
| Net Income | (45.43 M) | ||||
| Cash And Equivalents | 122.01 M | ||||
| Cash Per Share | 2.82 X | ||||
| Total Debt | 1.52 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 15.02 X | ||||
| Book Value Per Share | 0.73 X | ||||
| Cash Flow From Operations | (37.69 M) | ||||
| Short Ratio | 9.95 X | ||||
| Earnings Per Share | (0.79) X | ||||
| Target Price | 10.25 | ||||
| Number Of Employees | 32 | ||||
| Beta | 1.34 | ||||
| Market Capitalization | 104.41 M | ||||
| Total Asset | 97.19 M | ||||
| Retained Earnings | (384.18 M) | ||||
| Working Capital | 81.63 M | ||||
| Current Asset | 16.9 M | ||||
| Current Liabilities | 4.78 M | ||||
| Net Asset | 97.19 M |
About Cardiff Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cardiff Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiff Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiff Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Cardiff Stock please use our How to Invest in Cardiff Oncology guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Can Biotechnology industry sustain growth momentum? Does Cardiff have expansion opportunities? Factors like these will boost the valuation of Cardiff Oncology. Projected growth potential of Cardiff fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cardiff Oncology demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Understanding Cardiff Oncology requires distinguishing between market price and book value, where the latter reflects Cardiff's accounting equity. The concept of intrinsic value - what Cardiff Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cardiff Oncology's price substantially above or below its fundamental value.
It's important to distinguish between Cardiff Oncology's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cardiff Oncology should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cardiff Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.